Read the research behind the results
The Apollo technology’s efficacy and safety have been validated in over a dozen independent and university-led trials, and there are more studies in progress focused on stress-management, sleep, and stress-related conditions. The Apollo Neuro Research Team is excited to share these promising results in our mission to help people take control of their stress and live healthier, happier lives.
🎖️We are proud to share that two of our studies are double-blind randomized placebo controlled crossover trials.
What does that mean? A double-blind randomized placebo-controlled crossover trial is the gold-standard in scientific methodology. These studies are accepted as producing results that are untainted by bias. The sample size in these rigorous trials are more powerful than a study that simply compares two groups. Each subject in a double-blind randomized placebo-controlled crossover trial is exposed to every condition of the trial multiple times.
Completed studies and preliminary results
NEW: Pilot Study of Apollo for Psychedelic Harm Reduction
Results
90% of participants reported that decreased anxiety after the psychedelic medicine was ingested and before the psychedelic effects ensued. 95% of participants reported improved feelings of control/agency and calm during the experience when challenging subject matter came up or when they felt they were having a 'bad trip'. 84% of participants reported that Apollo use following their psychedelic experience improved their 'integration' of what they learned during their experience.
Trial type
Pilot Survey Study (not IRB approved)
Population
Apollo wearable users
Sample size
517
Primary outcomes
Anxiety
*This study was conducted by the Apollo Neuroscience Research Team
NEW: Wearable in Systemic Sclerosis: A Pilot Study of the Apollo Wearable Demonstrates Improvement in Fatigue, Raynaud Phenomenon and Quality-of-Life in Patients with Systemic Sclerosis
Partner
University of Pittsburgh Medical Center
Results
After 4 weeks of using the Apollo wearable, participants reported less fatigue (p < 0.001). The average daily number of Reynaud attacks declined (p < 0.01), as did the Raynaud condition score (p < 0.001) after 4 weeks of use. Average device usage (2.87 hours per day) far exceeded the requested time, and no adverse events occurred. Improvements were also observed in quality of life (QoL) in physical function (p < 0.01), sleep disturbance (p = 0.001), and ability to participate in social roles and activities (p < 0.001). Significant improvements were also noted for depression (p < 0.01) and disability (p < 0.05) measures.
Trial type
Open-Label Prospective Interventional Study (IRB Approved)
Population
Systemic Sclerosis patients
Sample size
25
Apollo vibrations improve HRV in a double-blind randomized placebo-controlled crossover trial
Partner
University of Pittsburgh
Results
Statistically significant increase in HRV
Trial type
Double-Blind Randomized Placebo-Controlled Crossover Trial (IRB Approved)
Population
University of Pittsburgh club and varsity athletes
Sample size
22
Primary outcomes
Improved HRV, Faster recovery
🎖️Double-blind randomized placebo controlled crossover trial
Apollo Remote Observational Sleep Study
Partners
University of Pittsburgh Medical Center & The Board of Medicine
Preliminary results
Those who use the Apollo wearable consistently (3+ hours a day, 5+ days a week, during the day and night) over 3 months see the biggest improvements in sleep and cardiovascular recovery metrics. Over 30 minutes more sleep per night.
Trial type
Real-World Observational Study (IRB Approved)
Population
Apollo wearable users (18+) who also own Oura Rings
Sample size
582
Primary outcomes
Sleep quality and cardiovascular metrics (heart rate, HRV) as measured by ŌURA Ring
*This study is sponsored by Apollo Neuro
Publication status
Under Peer-Review
Apollo Remote Prospective Interventional Sleep Study
Partners
University of Pittsburgh Medical Center & The Board of Medicine
Results
Study complete. Analysis ongoing.
Trial type
Real-World Prospective Interventional Study (IRB approved)
Population
Apollo wearable users (18+) who also own Oura Rings
Sample size
300
Publication status
In Preparation
*This study is sponsored by Apollo Neuro
Double-blind randomized placebo-controlled crossover study of Apollo to improve HRV and cognitive performance
Partners
University of Pittsburgh
Results
In a double-blind randomized placebo-controlled crossover clinical trial, Apollo vibrations improved heart rate variability (HRV) and cognitive performance under stress.
Trial type
Double-Blind Randomized Placebo-Controlled Crossover Trial (IRB Approved)
Population
Healthy adults (18+)
Sample size
38
Primary outcomes
Cognitive performance
Secondary outcomes
HRV, self-reported stress, pupil dilation, galvanic skin response, respirations, EEG
🎖️Double-blind randomized placebo controlled crossover trial
Publication status
In Preparation
Open-label trial of Apollo to improve access to meditative states
Partners
University of Pittsburgh
Results
Both experienced and naive meditators achieve significantly deeper meditative states with the Apollo wearable.
Trial type
Open-Label Prospective Interventional Study (IRB Approved)
Population
Healthy adults (18+)
Sample size
50 (25 experienced meditators, 25 without meditation experience)
Primary outcomes
Positive affect, HRV
Secondary outcomes
Negative affect, task performance, EEG
Publication status
In Preparation
Apollo Wearable for Improving Pain and Fatigue in Metastatic Breast Cancer (MBC) Patients
Partners
University of Pittsburgh Medical Center
Trial type
Open-Label Prospective Interventional Study (IRB approved)
Population
Women diagnosed with metastatic breast cancer
Sample size
30
Results
Statistically and clinically significant improvements were observed
Primary outcomes
Sleep, fatigue, pain, mood, and quality of life
Publication status
In Preparation
Apollo in Veterans With a History of PTSD
Partners
Rocky Mountain VA Hospital (Denver, CO)
Trial type
Open-Label Prospective Interventional Study (IRB Approved)
Population
Veterans with a diagnosis of PTSD
Sample size
65
Results
Statistically and clinically significant improvements were observed.
Primary outcomes
Symptoms of PTSD and depression
Publication status
In Preparation
Assessing a Peripheral Nerve Stimulator (Apollo) for Remediating Cognitive and Executive Dysfunction in Adolescents with Post-Concussion Symptoms
Partners
University of South Carolina
Trial type
Open-Label Prospective Interventional Study (IRB approved)
Population
Teens with a history of concussion diagnosed with post-concussion syndrome
Sample size
60
Results
Statistically significant improvements were observed.
Primary outcomes
HRV, sleep and post-concussive symptoms
Publication status
In Preparation
A Wearable Wrist-Worn Nerve Stimulator for Remediating Autonomic Dysfunction Associated Chronic Migraine/Headache and Mood Disturbance in Adolescents
Partner
University of South Carolina
Trial type
Open-Label Prospective Interventional Study (IRB Approved)
Population
Clinic patients (ages 10+) who the clinicians have diagnosed with chronic headache/migraine and deemed suitable for the use of the device
Sample Size
60
Results
Statistically significant results were observed.
Primary Outcomes
Evaluate the effectiveness of the Apollo Device for remediating clinical symptoms including pain, anxiety, depression and sleep disturbance via comparison of scores at initial evaluation and follow-up appointments.
Publication status
In Preparation
Acute Nerve Stimulation for Enhancing Human and Cognitive Performance
Partner
University of South Carolina
Trial type
Single-Blind Randomized Placebo-Controlled Trial
Population
Recreationally active adults (age 18-35) with a history of traumatic brain injury (TBI). ROTC from The University of South Carolina and Benedict College
Sample Size
35
Results
Statistically significant results were observed.
Primary Outcomes
The purpose of this within subject, repeated measures study is to evaluate the effectiveness of Apollo’s stimulation compared to sham stimulation. The main outcome of interest is the Apollo Neuro Device’s influence on physiological function to mediate human performance and cognition. Physiological function will be derived from metrics of heart rate variability and blood-based biomarkers, whilst human performance will be evaluated using tasks that assess cognitive domains of executive function, reaction time, and memory.
Publication status
In Preparation
Preventing Burnout in Medical and Pharmacy Students Study
Partner
Washington State University
Trial type
Open-Label Prospective Interventional Study
Population
Medical and Pharmacy students enrolled at Washington State University
Sample Size
80
Results
Statistically significant improvements were observed
Primary Outcomes
Burnout scores
Publication status
In Preparation
Open-label trial of Apollo to improve symptoms in patients with PTSD
Partners
University of Pittsburgh
Results
Apollo use over 2 weeks significantly improved symptom scores in subjects with PTSD
Population
Adults with diagnosed PTSD (Ages 18-58)
Sample size
16
Primary outcome
Change in PTSD symptoms and HRV before and after Apollo use.
Pilot study of Apollo in nurses to reduce stress and signs of burnout
Partners
Skilled nursing facility • Pittsburgh, PA
Results
In an open-label evaluation to improve employee wellness and quality of care in nursing home staff, the Apollo wearable reduced stress in nursing staff by up to 40% in two weeks.
Population
Nurses
Sample size
12
Primary outcome
Quality of life, mood, and stress symptoms
Pilot study of Apollo to improve focus and calm in children with ADHD and anxiety disorders
Partners
Children’s Integrated Center for Success (CICS)
Results
Neurodevelopmental pediatrics pilot study shows improvement in mood, behavior, engagement, and stress reduction in children and adolescents with anxiety and ADHD.
Population
Pediatrics age 7-17 across a breadth of diagnostic categories, like mood and anxiety disorders, as well as impulse control, autism, and ADHD
Sample size
15
Primary outcome
Mood & behavior, stress reduction, engagement
Pilot study of Apollo to improve athletic performance, recovery, and HRV
Partners
Division 1 University Athletics Department
Results
In a study of collegiate athletes, the Apollo wearable improved heart rate variability (HRV), athletic performance and recovery.
Population
Collegiate athletes (18+)
Sample size
40
Primary outcome
Athletic performance and recovery, cardiovascular metrics (HRV, heart rate)
Studies in progress
Apollo for Symptom Management in Long-COVID
Partner
The Board of Medicine
Trial type
Open-Label Prospective Study (IRB approved)
Population
Adults >18yo who have been diagnosed with COVID
Sample Size
200
Primary Outcomes
Evaluate the impact of Apollo wearable use on symptoms and quality of life in
those experiencing post-COVID conditions.
*This study is sponsored by Apollo Neuro
Status
Recruiting Subjects (Remote Participants Accepted)
The Apollo Device in Systemic Sclerosis for the Management of fatigue, Raynaud Phenomenon and quality of life
Partner
University of Pittsburgh Medical Center & NIH
Trial type
Double-Blind Randomized Placebo-Controlled Clinical Trial (IRB approved)
Population
Adults >18yo who have been diagnosed with Systemic Sclerosis
Sample Size
160
Primary Outcomes
Fatigue, Raynaud’s symptoms, and quality of life
🎖️Double-blind randomized placebo-controlled trial
Status
Recruiting Subjects
Apollo for Sustaining Remission From PTSD Using Tuned Vibroacoustic Stimulation (TVS) Following MDMA-Assisted Psychotherapy
Partner
The Multidisciplinary Association for Psychedelic Studies (MAPS) & The Board of Medicine
Trial type
Open-Label Prospective Interventional Study (IRB approved)
Population
Any past participant in a MAPS trial of MDMA-assisted therapy who has completed their final follow up period with MAPS, including participants who received placebo and those who dropped out of the study prior to completion, are eligible to participate.
Sample Size
200
Primary Outcomes
To examine how use of Apollo can influence PTSD symptoms and remission rates over
two years after participation in any MAPS trial of MDMA-assisted therapy.
*This study is sponsored by Apollo Neuro
Status
Recruiting Subjects (Remote Participants Accepted)
Apollo for Preventing Burnout in Physicians Study
Partner
University of Pittsburgh Medical Center (UPMC)
Trial type
Open-Label Prospective Interventional Study (IRB approved)
Population
Physicians in residency training or clinical practice at UPMC
Sample Size
300
Primary Outcomes
This study is aimed at evaluating the impact of HRV-improving wearable technology on physician well-being related to preventing burnout.
Status
Recruiting Subject
Evaluating the Efficacy of the Apollo System for Children With ADHD
Partner
Michigan State University & The Board of Medicine
Trial type
Double-Blind Randomized Placebo-Controlled Study (IRB approved)
Population
Children under 18yo with a history of diagnosed ADHD
Sample Size
100
Primary Outcomes
To examine the effect of wearing Apollo on symptoms associated with ADHD.
🎖️Double-blind randomized placebo-controlled trial
Status
Recruiting Subjects
Apollo to Augment Ketamine Therapy First Responder PTSD Study
Partner
Dr. Pamela Kryskow; Roots to Thrive
Trial type
Open-Label Prospective Interventional Study (IRB Approved)
Population
First responders diagnosed with PTSD
Sample Size
20
Primary Outcomes
Improved symptoms of PTSD and improved response rates to ketamine therapy
Status
Recruiting Subjects
Remote Real World Observational Sleep Study of the Apollo Wearable
Partner
The Board of Medicine
Trial type
Real World Observational Study (IRB Approved)
Population
Adults over 18yo with either an Oura Ring or Apple Watch
Sample Size
6000
Primary Outcomes
Improved sleep as measured by Oura Ring and Apple Watch
*This study is sponsored by Apollo Neuro
Status
Recruiting Subjects (Remote Participants Accepted)
Apollo for Preventing Burnout in Surgeons Study
Partner
UCLA
Trial type
Open-Label Prospective Interventional Study
Population
Anesthesiologists and surgeons in practice or training at UCLA Medical Center Hospitals
Sample Size
80
Status
IRB submission in progress
Apollo to Improve Outcomes in Ketamine Therapy
Partner
The Board of Medicine
Trial type
Open-Label Prospective Interventional Study
Population
Adults over 18yo
Sample Size
500
Status
IRB submission in progress
Apollo to Improve Sexual Health and Fertility
Partner
The Board of Medicine
Trial type
Open-Label Prospective Interventional Study
Population
Adults over 18yo
Sample Size
500
Status
IRB submission in progress
Apollo for Weight Loss
Partner
The Board of Medicine
Trial type
Open-Label Prospective Interventional Study
Population
Adults over 18yo
Sample Size
500
Status
IRB submission in progress
Apollo to Improve Chronic Pain
Partner
The Board of Medicine
Trial type
Open-Label Prospective Interventional Study
Population
Adults over 18yo
Sample Size
500
Status
IRB submission in progress
